GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.
A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol ...
In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
Carolina Rudah / iStock What is the Maximum Recommended Semaglutide Dose for Weight Loss? The maximum recommended semaglutide dose for weight loss is 2.4 milligrams (mg) per week. Your healthcare ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback